|
|
||||||||
Ann Thorac Surg 2001;71:S98-S102
© 2001 The Society of Thoracic Surgeons
a Department of Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Ruhr University of Bochum, Bad Oeynhausen, Germany
Address reprint requests to Dr El-Banayosy, Klinik für Thorax- und Kardiovaskularchirurgie, Herzzentrum NRW, Georgstr 11, D-32545 Bad Oeynhausen, Germany
e-mail: abanayosy{at}hdz-nrw.de
Presented at the Fifth International Conference on Circulatory Support Devices for Severe Cardiac Failure, New York, NY, Sept 1517, 2000.
Abstract
Background. A variety of sophisticated devices have been developed for mechanical circulatory support in patients bridged to cardiac transplantation. Based on 13 years experience, we have developed specific protocols for patient selection and management for different devices.
Methods. The principal systems applied in the bridge-to-transplant cohort are the Thoratec ventricular assist device (n = 144, mean duration of support 53 ± 57 days), the Novacor left ventricular assist system (LVAS) (n = 85, mean duration of support 154 ± 15 days), and the HeartMate LVAS (n = 54, mean duration of support 143 ± 142 days). The Thoratec device is used for biventricular assistance or if the duration of support is expected to be less than 6 months. For long-term support, either the Novacor or HeartMate LVAS are preferred.
Results. Despite careful postoperative patient management, this group of patients is prone to a variety of complications. Bleeding occurred in 22% to 35%, right heart failure in 15% to 26%, neurologic disorders in 7% to 28%, infection in 7% to 30%, and liver failure in 11% to 20% of patients. Complications varied with the device applied and the patients preoperative condition. A total of 73 patients were discharged from hospital for a mean period of 184 days; this cumulative experience amounted to 37.5 patient-years.
Conclusions. The Novacor and the HeartMate systems offer the additional possibility of discharging patients during support if they fulfill certain criteria. The main reasons for rehospitalization were thromboembolic and infectious complications.
This article has been cited by other articles:
![]() |
T. Ota, T. W. Gilbert, S. F. Badylak, D. Schwartzman, and M. A. Zenati Electromechanical characterization of a tissue-engineered myocardial patch derived from extracellular matrix J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 979 - 985. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schenk, A. El-Banayosy, W. Prohaska, L. Arusoglu, M. Morshuis, W. Koester-Eiserfunke, L. Kizner, E. Murray, P. Eichler, R. Koerfer, et al. Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1373 - 1381. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. El-Banayosy, D. Cobaugh, A. Zittermann, L. Kitzner, L. Arusoglu, M. Morshuis, H. Milting, G. Tenderich, and R. Koerfer A Multidisciplinary Network To Save the Lives of Severe, Persistent Cardiogenic Shock Patients Ann. Thorac. Surg., August 1, 2005; 80(2): 543 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. El-Banayosy, L. Arusoglu, M. Morshuis, L. Kizner, G. Tenderich, P. Sarnowski, H. Milting, and R. Koerfer CardioWest Total Artificial Heart: Bad Oeynhausen Experience Ann. Thorac. Surg., August 1, 2005; 80(2): 548 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Haddad, R. G. Masters, P. J. Hendry, A. Kawai, J. P. Veinot, G. Lavallee, and T. V. Mussivand Intercontinental LVAS Patient Transport Ann. Thorac. Surg., November 1, 2004; 78(5): 1818 - 1820. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Collart, H. Feier, D. Metras, and T. G. Mesana A safe, alternative technique for off-pump left ventricular assist device implantation in high-risk reoperative cases Interactive CardioVascular and Thoracic Surgery, June 1, 2004; 3(2): 286 - 288. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.D. Dowling, S.J. Park, F.D. Pagani, A.J. Tector, Y. Naka, T.B. Icenogle, V.L. Poirier, and O.H. Frazier HeartMate(R) VE LVAS design enhancements and its impact on device reliability Eur. J. Cardiothorac. Surg., June 1, 2004; 25(6): 958 - 963. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Morgan, R. John, V. Rao, A. D. Weinberg, B. J. Lee, P. A. Mazzeo, M. R. Flannery, J. M. Chen, M. C. Oz, and Y. Naka Bridging to transplant with the HeartMate left ventricular assist device: The Columbia Presbyterian 12-year experience J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1309 - 1316. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kleikamp, A. Maleszka, N. Reiss, B. Stuttgen, and R. Korfer Determinants of mid- and long-term results in patients after surgical revascularization for ischemic cardiomyopathy Ann. Thorac. Surg., May 1, 2003; 75(5): 1406 - 1412. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Kukuy, M. C. Oz, and Y. Naka Long-Term Mechanical Circulatory Support Card. Surg. Adult, January 1, 2003; 2(2003): 1491 - 1506. [Full Text] |
||||
![]() |
J.M. Grinda, C.H. Latremouille, P. Chevalier, N. D'Attelis, F. Boughenou, R. Guillemain, A. Deloche, and J.N. Fabiani Bridge to transplantation with the DeBakey VAD(R) axial pump: a single center report Eur. J. Cardiothorac. Surg., December 1, 2002; 22(6): 965 - 970. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Miyagawa, Y. Sawa, S. Taketani, N. Kawaguchi, T. Nakamura, N. Matsuura, and H. Matsuda Myocardial Regeneration Therapy for Heart Failure: Hepatocyte Growth Factor Enhances the Effect of Cellular Cardiomyoplasty Circulation, May 28, 2002; 105(21): 2556 - 2561. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Brewer, H. C. M. Lwamba, M. P. Murtaugh, A. C. Palmenberg, C. Brown, and M. K. Njenga Porcine Encephalomyocarditis Virus Persists in Pig Myocardium and Infects Human Myocardial Cells J. Virol., December 1, 2001; 75(23): 11621 - 11629. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |